Session » Reproductive Issues in Rheumatic Disorders Poster

Date: Monday, November 6, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1308

Answering Reproductive Health Questions That Your Patients Want to Know: Impediments to Family Building and Risks of Contraception

9:00AM-11:00AM: Abstract Number: 1309

Characteristics and Outcomes of Prospectively Reported Pregnancies Exposed to Certolizumab Pegol from a Safety Database

9:00AM-11:00AM: Abstract Number: 1301

Congenital Heart Defects in Children Born to Mothers with Rheumatic Disease and Anti-Ro and/or Anti-La Antibodies

9:00AM-11:00AM: Abstract Number: 1307

Contraceptive Use in Patients with Rheumatologic Disease on Teratogenic Medications: Rate of Use and Related Factors

9:00AM-11:00AM: Abstract Number: 1297

Hydroxychloroquine in Lupus Pregnancy: A Meta-Analysis of Individual Participant Data

9:00AM-11:00AM: Abstract Number: 1296

Hydroxychloroquine Level Decreases throughout Pregnancy: Implications for Maternal and Neonatal Outcomes

9:00AM-11:00AM: Abstract Number: 1293

Indications for Cesarean Delivery in Systemic Lupus Erythematosus Pregnancies

9:00AM-11:00AM: Abstract Number: 1315

Influence of Rheumatoid Arthritis and Axial Spondyloarthritis on Pregnancy Complications, Pregnancy Outcome and Delivery Mode

9:00AM-11:00AM: Abstract Number: 1304

Lack of Uptake of Prophylactic Human Papilloma Virus (HPV) Vaccination Among Women with SLE in Saginaw Valley, a High Risk Population

9:00AM-11:00AM: Abstract Number: 1292

Long-Term Follow-up of 320 Chilren Born to Mothers with Systemic Autoimmune Diseases: A Multicentre Survey from 24 Rheumatology Centers in Italy

9:00AM-11:00AM: Abstract Number: 1302

Luteinized Unruptured Follicle Syndrome in Young Female with Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 1310

Maternal and Fetal Outcomes in a Cohort of Patients Exposed to Tumor Necrosis Factor Inhibitors throughout Pregnancy

9:00AM-11:00AM: Abstract Number: 1317

Obstetric Outcomes in Women with Rheumatoid Arthritis: Results from Nationwide Inpatient Sample Database 2003-2011

9:00AM-11:00AM: Abstract Number: 1313

Oral Corticosteroid Use during Pregnancy and Risk of Preterm Birth in Women with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1299

Patient-Reported Disease Activity and Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus and Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1303

Polycystic Ovarian Syndrome in Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 1306

Predictors of Contraceptive Use Among Reproductive-Age Women with Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1311

Pregnancy Outcome in Chinese Women with Rheumatic Disease Treated By Leflunomide (LEF)

9:00AM-11:00AM: Abstract Number: 1295

Pregnancy Outcome in Patients with SLE Compared to Patients with Other Inflammatory Rheumatic Diseases: Real World Data from a Prospective Pregnancy Register

9:00AM-11:00AM: Abstract Number: 1312

Pregnancy Outcomes in Male Patients Using Anti-Tumor Necrosis Factor Alpha Patients with Inflammatory Arthritis; Hur-BIO Real Life Experiences

9:00AM-11:00AM: Abstract Number: 1314

Pregnancy Outcomes in Patients with Psoriasis: A Nationwide Population-Based Study

9:00AM-11:00AM: Abstract Number: 1290

Preterm Birth Phenotypes in Women with Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 1291

Preterm Delivery Phenotypes in SLE Pregnancies

9:00AM-11:00AM: Abstract Number: 1316

Risk of Preterm Delivery Associated with Perinatal Exposure to Dmards in Women with Inflammatory Arthritis: A Population-Based Cohort Study

9:00AM-11:00AM: Abstract Number: 1300

The Italian Registry of Autoimmune Congenital Heart Block (Lu.Ne Registry): Report of the First Year of Activity

9:00AM-11:00AM: Abstract Number: 1294

Time to Pregnancy in Women with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1298

Tough Choices: Understanding the Medication Decision-Making Process for Women with Inflammatory Arthritis during Pregnancy and Lactation

9:00AM-11:00AM: Abstract Number: 1305

Use of Estrogen-Containing Contraceptives Among SLE Women with and without Contraindications to Estrogen

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].